PRIMATE MODEL EVALUATION OF A TISSUE ENGINEERED HEART VALVE

组织工程心脏瓣膜的灵长类动物模型评估

• 批准号: 8357672
• 负责人: Richard A Hopkins
• 金额: $ 0.1万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357672
• 关键词: Allografting; Biological; Biology; Cardiovascular system; Cells; Child; Chronic; Clinical; Complex; Engineering; Evaluation; Excision; Funding; Grant; Heart Valves; Human; Immune; Infant; Inflammatory; Lung; Mediating; Modeling; National Center for Research Resources; Papio; Patients; Performance; Primates; Principal Investigator; Process; Research; Research Infrastructure; Research Project Grants; Resources; Safety; Sheep; Source; Structural Protein; Testing; Therapeutic; Tissue Engineering; Translational Research; Transplantation; United States National Institutes of Health; Xenograft procedure; cost; design; immunogenic; in vivo; novel; preclinical safety; response; safety testing; scaffold; semilunar valve; tool; young adult

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. This translational research project is prompted by the need to develop new evaluative tools to assess the preclinical safety of tissue engineered biological heart valves intended for use in infants, children and young adults. Chronic in vivo studies in sheep may not be sufficient to adequately evaluate primate-specific complex biology, immune and inflammatory-mediated responses that are critical factors expected to significantly impact the safety, performance and therapeutic durability of a tissue engineered biological heart valve for human clinical use. Such a tissue engineered cardiovascular construct, by definition, includes both cells (derived from the patient/recipient), and structural proteins (derived from the donor heart valve). The putative prototypical tissue engineered pulmonary valved conduit scaffold to be tested consists of either an allograft (homograft; ie, baboon species for orthotopic transplant) or a xenograft (human semilunar valve) scaffold. Both test valve types will have been engineered to effect removal of donor cells and reduce antigenicity (using our novel decellularization process). This design will test the safety of the acellular construct and the immunogenic and proinflammatory potential of allograft (papio) versus xenograft (human) structural proteins.

该副本是利用资源的众多研究子项目之一 由NIH/NCRR资助的中心赠款提供。对该子弹的主要支持 而且，副投影的主要研究员可能是其他来源提供的 包括其他NIH来源。 列出的总费用可能 代表subproject使用的中心基础架构的估计量， NCRR赠款不直接向子弹或副本人员提供的直接资金。 这项翻译研究项目是由于需要开发新的评估工具来评估旨在用于婴儿，儿童和年轻人的临床前的安全性。 绵羊的慢性体内研究可能不足以充分评估灵长类动物特异性的复杂生物学，免疫和炎症介导的反应，这是预期的关键因素，可显着影响组织工程生物心脏瓣膜的安全性，性能和治疗耐用性。 从定义上讲，这种组织工程的心血管构建体包括两个细胞（源自患者/受体）和结构蛋白（源自供体心脏瓣膜）。 假定的原型组织工程肺动脉瓣导管支架要测试，由同种异体移植（同种异体移植；即，原位移植）或异种移植物（人类半路径）支架组成。 两种测试阀类型都将经过设计以实现供体细胞的去除并降低抗原性（使用我们的新型脱细胞过程）。 该设计将测试细胞构建体的安全性以及同种异体移植（Papio）与异种移植（人）结构蛋白的免疫原性和促炎潜力。